WallStSmart

Concord Medical Services Holdings (CCM)vsJohnson & Johnson (JNJ)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 21471% more annual revenue ($99.33B vs $460.51M). JNJ leads profitability with a 16.2% profit margin vs -20.2%. CCM appears more attractively valued with a PEG of 0.57. JNJ earns a higher WallStSmart Score of 57/100 (C).

CCM

Hold

43

out of 100

Grade: D

Growth: 5.3Profit: 2.0Value: 7.7Quality: 5.5
Piotroski: 6/9Altman Z: -0.95

JNJ

Buy

57

out of 100

Grade: C

Growth: 4.7Profit: 8.5Value: 2.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCMUndervalued (+67.1%)

Margin of Safety

+67.1%

Fair Value

$11.65

Current Price

$3.85

$7.80 discount

UndervaluedFair: $11.65Overvalued
JNJSignificantly Overvalued (-83.0%)

Margin of Safety

-83.0%

Fair Value

$144.12

Current Price

$271.17

$127.05 premium

UndervaluedFair: $144.12Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCM3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
57.4%10/10

Revenue surging 57.4% year-over-year

Debt/EquityHealth
-1.7310/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.578/10

Growing faster than its price suggests

JNJ3 strengths · Avg: 8.7/10
Market CapQuality
$615.87B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
25.1%8/10

Strong operational efficiency at 25.1%

Free Cash FlowQuality
$6.36B8/10

Generating 6.4B in free cash flow

Areas to Watch

CCM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$15.46M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-21.9%2/10

ROE of -21.9% — below average capital efficiency

Altman Z-ScoreHealth
-0.952/10

Distress zone — elevated risk

JNJ4 concerns · Avg: 2.8/10
P/E RatioValuation
38.8x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.822/10

Expensive relative to growth rate

EPS GrowthGrowth
-96.0%2/10

Earnings declined 96.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : CCM

The strongest argument for CCM centers on Revenue Growth, Debt/Equity, PEG Ratio. Revenue growth of 57.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.

Bear Case : CCM

The primary concerns for CCM are EPS Growth, Market Cap, Return on Equity.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.

Key Dynamics to Monitor

CCM profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.

JNJ carries more volatility with a beta of 0.21 — expect wider price swings.

CCM is growing revenue faster at 57.4% — sustainability is the question.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

JNJ scores higher overall (57/100 vs 43/100), backed by strong 16.2% margins. CCM offers better value entry with a 67.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Concord Medical Services Holdings

HEALTHCARE · MEDICAL CARE FACILITIES · China

Concord Medical Services Holdings Limited, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.

Visit Website →

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Want to dig deeper into these stocks?